Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus VEETIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus VEETIDS 250.
AMPICILLIN AND SULBACTAM vs VEETIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
VEETIDS '250' is an oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
250 mg orally every 8 hours for 7-10 days
None Documented
None Documented
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
2-3 hours in adults with normal renal function; prolonged to 24-40 hours in anuria/end-stage renal disease, requiring dose adjustment.
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Primarily renal (≥90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal (<5%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic